GSK team clinch­es pos­i­tive tri­al for the first po­ten­tial new TB vac­cine in a cen­tu­ry — with mil­lions of lives at stake

A Glax­o­SmithK­line crew of in­ves­ti­ga­tors has com­plet­ed their analy­sis of a Phase IIb tri­al for what they be­lieve could be the first big break­through in the tu­ber­cu­lo­sis vac­cine field in close to 100 years. And they say the fi­nal re­sults jus­ti­fy their en­thu­si­asm for fi­nal rounds of stud­ies aimed at study­ing a jab that has the po­ten­tial to slash the more than 1.5 mil­lion deaths per year at­trib­uted to TB.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER